Pioneering Breakthroughs in Vaccine Development.
Powered by Advanced Science
Our breakthroughs are built on a foundation of deep immunological understanding and state-of-the-art biotechnology platforms, including:
BiLipid™ mRNA Delivery
Enhanced stability and efficient delivery for mRNA vaccines.
SAMplify™ Self-Amplifying mRNA
Potent immunity at lower doses.
StructVax™ Structural Vaccinology
Precision antigen design.
AdaVant™ Adjuvant Systems
Tailored immune response enhancement.
Addressing Critical Global Health Challenges
Emerging Threats
Rapid response capabilities for pathogens with pandemic potential.
Respiratory Diseases
Advanced vaccines for RSV, influenza, and coronaviruses.
Persistent Diseases
Innovative approaches for TB, malaria, and neglected tropical diseases.
Global Access
Designing vaccines for worldwide reach and impact.
Latest Updates
Bilex Pharma Completes Patient Enrollment for Landmark Phase 3 Trial of RSV Vaccine Candidate BLX-RSV01 in Older Adults
Bilex Pharma today announced the successful completion of patient enrollment in the pivotal Phase 3 clinical trial (RSV-301) evaluating the…
Bilex Pharma’s Next-Generation COVID-19 Vaccine BLX-COVID19 Shows Superior Immune Response with Reduced Dosing in Phase 2 Trial
Bilex Pharma today announced highly encouraging results from its Phase 2 clinical trial evaluating BLX-COVID19, the company's next-generation COVID-19 vaccine…
Bilex Pharma Awarded £15 Million Grant from CEPI to Accelerate Development of Pandemic Preparedness Platform
Bilex Pharma is honoured to announce it has been awarded a significant grant of £15 million from the Coalition for…
Bilex Pharma’s Universal Influenza Vaccine Candidate Shows Promising Cross-Strain Protection in Phase 2b Interim Analysis
Bilex Pharma today announced promising interim results from its ongoing Phase 2b clinical trial evaluating BLX-FLU03, the company's investigational universal…
Bilex Pharma’s Dengue Vaccine Candidate BLX-DEN01 Demonstrates Balanced Immune Response Against All Four Serotypes in Phase 1 Trial
Bilex Pharma today announced positive topline results from the Phase 1 clinical trial of BLX-DEN01, its tetravalent dengue vaccine candidate.…
Bilex Pharma Announces Breakthrough in Thermostable Vaccine Technology, Enhancing Global Access Potential
Bilex Pharma today announced a significant advancement in its vaccine technology platform, achieving enhanced thermostability for its mRNA vaccine formulations.…